NEWS

Cromos Pharma begins operations in Kazakhstan Cromos™ Pharma, a premier full service regional contract research organization (CRO) announced that it has begun operations in Kazakhstan. The company has initiated three phase III trials in the region with the fourth study nearing finalization of the prelaunch phase. “Kazakhstan is an uncharted territory for most clinical trial organizations and as such it epitomizes

cromos-pharma-at-the-swiss-biotech-day-in-basel-on-4-may-2017

Cromos™ Pharma has published a white paper on the new EU clinical trial regulation (no. 536/2014) and investigator-led studies

Cromos™ Pharma received regulatory approval for the first ever ophthalmological clinical trial in Georgia Tbilisi, Georgia. February 21, 2017. On February 17, 2017 the State Regulation Agency for Medical Activities, Ministry of Labour, Health and Social Affairs of Georgia granted Cromos™ Pharma approval to conduct the very first ophthalmology trial in Georgia. This international Phase III study in patients with Dry Eye Disease will enroll patients at 3 specialized

Cromos Pharma has published a white paper that gives a comprehensive overview of clinical trial landscape in the Republic of Georgia, which is becoming a very attractive location for clinical trials In addition to lightning-fast startup times, robust enrollment and full compliance with the ICH-GCP you will also be pleasantly surprised by the high quality of the study data evidenced by 12 recent 100% NAI (No Action Indicated) reports from FDA inspections. Please follow the link to the whitepaper that may provide some additional insight into

DUBLIN, IRELAND–(Marketwired – October 24, 2016) – Cromos™ Pharma, a premier regional contract research organization announced today that Dr. Gearóid Tuohy has been appointed…